Drugs / IMD-1041
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00883584 Comparator | Jul 2008 → May 2009 | chronic obstructive pulmonary disease | Institute of Medicinal Molecular Design, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMD-1041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00883584 ↗ |
| Action | Inhibit | “Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor” CHEMBL3545168 ↗1“It is an IKKb inhibitor developed for the treatment of COPD.” NCT00883584 ↗ |
| Route | Oral | “multiple oral doses of 400 mg twice daily of IMD-1041” NCT00883584 ↗ |
| Target | IKBKB | “Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor” CHEMBL3545168 ↗ |